Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Nucynta CR Tapentadol Pain, moderate to moderately severe Do not list Complete
Nurtec ODT rimegepant Migraine, prevention Withdrawn
NuvaRing Etonogestrel/ethinyl estradiol Contraceptive, ring List with clinical criteria and/or conditions Complete
Ocaliva Obeticholic Acid Primary Biliary Cholangitis Reimburse with clinical criteria and/or conditions Complete
Ocrevus ocrelizumab multiple sclerosis, relapsing Reimburse with clinical criteria and/or conditions Complete
Ocrevus ocrelizumab Primary progressive multiple sclerosis Reimburse with clinical criteria and/or conditions Complete
Odefsey emtricitabine/rilpivirine/ tenofovir alafenamide HIV-1 infection Reimburse with clinical criteria and/or conditions Complete
Odomzo Sonidegib Basal Cell Carcinoma Do not reimburse Complete
Ofev nintedanib chronic fibrosing interstitial lung diseases Reimburse with clinical criteria and/or conditions Complete
Ofev Nintedanib Idiopathic pulmonary fibrosis List with clinical criteria and/or conditions Complete
Ogivri Trastuzumab Withdrawn
Olmetec Olmesartan medoxomil Hypertension List in a similar manner to other drugs in class Complete
Olmetec Plus Olmesartan medoxomil + hydrochlorothiazide Hypertension List in a similar manner to other drugs in class Complete
Olumiant baricitinib Alopecia areata, severe Active
Olumiant baricitinib Arthritis, Rheumatoid Reimburse with clinical criteria and/or conditions Complete
Omnaris Ciclesonide nasal spray Allergic Rhinitis (seasonal and perennial) Do not list Complete
Omnitrope Somatropin (rDNA origin) Growth hormone deficiency in children and adults N/A Complete
Omvoh mirikizumab Ulcerative colitis Reimburse with clinical criteria and/or conditions Complete
Onbrez Indacaterol Chronic obstructive pulmonary disease List in a similar manner Complete
Oncaspar pegaspargase Adult Acute Lymphocytic Leukemia (ALL) Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. Not filed
Ondexxya andexanet alfa Reversal of FXa inhibitor anticoagulant effects Do not reimburse Complete
Onglyza Saxagliptin Diabetes mellitus (Type 2) Do not list Complete
Onglyza Saxagliptin Diabetes mellitus, type 2 Withdrawn
Onglyza Saxagliptin Diabetes mellitus, type 2 List with criteria/condition Complete
Onivyde Irinotecan Liposome Metastatic Pancreatic Cancer Reimburse with clinical criteria and/or conditions Complete